Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Financial performance shows revenue growth but a significant net loss. Product updates are promising, with positive trial results and optimistic guidance for Cushing's syndrome and oncology drugs. However, operational challenges, regulatory risks, and competitive pressures persist. The Q&A reveals confidence in relacorilant and Lifyorli but highlights market competition and supply chain issues. No share buyback or dividend program is mentioned. Considering the market cap and mixed outlook, the stock price is likely to remain stable, with a neutral sentiment over the next two weeks.
Key Financial Performance
Revenue $164.9 million in Q1 2026, up from $157.2 million in Q1 2025, reflecting increased demand for medications.
Net Loss $31.8 million in Q1 2026, compared to net income of $20.5 million in Q1 2025, reasons not explicitly mentioned.
Cash and Investments $515 million as of March 31, 2026, no year-over-year comparison or reasons provided.
Lifyorli Trial Results Patients treated with Lifyorli and nab-paclitaxel experienced a 35% reduction in risk of death (hazard ratio of 0.65) compared to nab-paclitaxel monotherapy, with a p-value of 0.0004.
DAZALS Trial Results Patients receiving 300 mg of dazucorilant showed an 84% reduction in risk of death at 1 year (p-value 0.0009) and 87% at 2 years (p-value < 0.0001) compared to placebo.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lifyorli Approval: FDA approved Lifyorli for platinum-resistant ovarian cancer 3.5 months ahead of its PDUFA date. The drug demonstrated a 35% reduction in risk of death in its pivotal trial, ROSELLA. Early adoption is strong, with over 200 physicians prescribing it within 36 days of launch. Lifyorli is expected to exceed $1 billion in annual revenue in the U.S. by the end of the decade.
Relacorilant Development: Relacorilant is being developed for Cushing's syndrome and various solid tumors. Positive results from the GRACE trial support its NDA submission. Oncology trials are ongoing, with results expected by the end of this year and next year.
Dazucorilant for ALS: Dazucorilant showed an 84% reduction in risk of death at 1 year and 87% at 2 years in ALS patients during the DAZALS trial. A Phase III trial is planned for later this year.
Miricorilant for MASH: Miricorilant showed promising Phase Ib results in reducing liver fat and improving liver health markers. The Phase IIb MONARCH trial is fully enrolled, with results expected by year-end.
Cushing's Syndrome Market Expansion: CATALYST and MOMENTUM studies revealed high prevalence of hypercortisolism in patients with resistant diabetes and hypertension. These findings are expected to drive increased screening and treatment, potentially growing the Cushing's syndrome business to $2 billion annually by the end of the decade.
Oncology Market Expansion: Lifyorli's approval and ongoing trials for relacorilant in various cancers are expected to significantly expand Corcept's oncology market presence.
Revenue Growth: First-quarter 2026 revenue was $164.9 million, up from $157.2 million in the prior year. Revenue guidance for 2026 has been increased to $950 million to $1.05 billion.
Specialty Pharmacy Transition: Transition to a new specialty pharmacy vendor has been successful, with improved patient onboarding and prescription fulfillment.
Focus on Cortisol Modulation: Corcept is expanding its focus on cortisol modulation across endocrinology, oncology, and other therapeutic areas, including ALS and MASH.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue impact due to insurance reauthorization procedures: Revenue dips in the first quarter as insurance companies impose reauthorization procedures that interrupt patient coverage for a month or two. This leads to a temporary revenue loss despite providing free drugs to bridge the gap.
Revenue impact from new patient onboarding: New patients provide less revenue initially as payer coverage is secured and doses are titrated. This delays the full revenue impact of new patient additions.
Insurance prior authorization backlog: The transition to a new specialty pharmacy vendor has created a backlog in insurance prior authorizations, delaying revenue realization.
Regulatory and approval risks: The company faces regulatory hurdles for the approval of new drugs like relacorilant, which could impact future growth if not approved.
Operational challenges in oncology drug launch: Although the launch of Lifyorli has been successful, scaling operations and ensuring broad adoption remain challenges.
Market adoption of new findings: The adoption of findings from the CATALYST and MOMENTUM studies by physicians is gradual, delaying the full realization of their impact on screening and treatment practices.
Competition in oncology and endocrinology: The company operates in highly competitive markets, which could impact its ability to capture market share and sustain growth.
Supply chain and manufacturing risks: Ensuring the availability of drugs like Lifyorli and scaling manufacturing to meet demand could pose challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has increased its 2026 revenue guidance to $950 million to $1.05 billion.
Cushing's Syndrome Business Growth: The company expects its current Cushing's Syndrome business to grow to at least $2 billion in annual revenue by the end of this decade. Growth will accelerate further when relacorilant becomes available.
Lifyorli Revenue Expectations: Lifyorli is expected to exceed $1 billion in annual revenue in the United States by the end of the decade.
Oncology Trials and Expansion: The first arm of the BELLA trial will produce results by the end of this year, with other ongoing oncology trials expected to produce results by the end of next year. Successful results could increase the number of patients relacorilant might help by fivefold.
ALS Treatment Development: A pivotal trial for dazucorilant in ALS is planned to start later this year, following positive Phase II findings.
MASH Treatment Development: Results from the Phase IIb MONARCH trial in patients with MASH are expected by year-end. Positive results would support advancement to Phase III.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: The term 'dividends' was mentioned once in the context of the specialty pharmacy vendor's work yielding 'steady dividends' reflected in revenue over the coming months. However, this appears to be a metaphorical use rather than a discussion of a formal dividend program for shareholders.
Share Buyback Program: There was no mention of a share buyback program in the transcript.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:With the updated guidance, should we assume that it's mostly relacorilant contribution? Have any assumptions changed on Korlym?
A:The endocrine business represents the bulk of the guidance range due to the current state of oncology. Updates include approval, publication of ROSELLA results in The Lancet, and inclusion in NCCN guidelines. Strong fundamentals in the Cushing's syndrome business are expected to translate to revenue soon, leading to a confident raise in the guidance range.
Q:Can you talk to positioning versus KEYTRUDA in practice and how we should think about that?
A:Lifyorli competes in a subset of the market where KEYTRUDA is approved for a PD-L1 population. Lifyorli's ROSELLA trial data shows strong overall survival, safety, tolerability, and convenience, leading to a preference among physicians and a preferred status in treatment guidelines.
Q:How does nenocorilant differ from relacorilant, and what drives your development decisions there?
A:Nenocorilant has unique properties and has shown strong activity in animal models in combination with immunotherapy. It is being tested in a Phase I study to guide further development into Phase II, focusing on its potential as a partner with immunotherapy like nivolumab.
Q:What proportion of platinum-resistant ovarian cancer prescribers do you expect to convert to Lifyorli, especially with the NCCN preferred designation?
A:The company is targeting 5,000 physicians who account for 90% of the volume. Over 200 prescribers were captured in the first month, with adoption expected across community oncology, gynecology, and academic settings. The drug is expected to become a market leader in a short timeframe.
Q:What should we think about for the Phase III design of DAZALS, including dose, endpoints, and timing?
A:The Phase III study will focus on the 300-milligram dose, with survival as the endpoint. It will likely be a placebo-controlled trial, designed to replicate the success of the DAZALS trial. The trial is set to start this year, with patient enrollment by year-end.
Q:Are you looking to add another specialty pharmacy for the Korlym business to handle increased scripts?
A:The current pharmacy, Curant, has managed the transition and increased prescriptions well. However, as the business grows, the company plans to expand the network, with additional support expected in the fourth quarter of this year.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses provided sufficient detail and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AACE document
ACC month
American Association
Association Clinical
Atabak Demand
CATALYST practice
Cardiology ACC
Care American
Clinical Endocrinology
Corcept FDA
Demand medication
Division Sean
Endocrinology AACE
FDA division
Lancet article
Lancet oncologist
Meeting publication
NDA trial
Oncology Division
Prescriptions
ROSELLA
access
adoption
biomarker
coverage
day approval
efficacy safety
end decade
field
insurance
medication record
number patient
patient diabetes
patient medication
payer
physician practice
record number
safety profile
start
team
CORT Transcript
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call presents mixed signals. Financial performance shows revenue growth but a significant net loss. Product updates are promising, with positive trial results and optimistic guidance for Cushing's syndrome and oncology drugs. However, operational challenges, regulatory risks, and competitive pressures persist. The Q&A reveals confidence in relacorilant and Lifyorli but highlights market competition and supply chain issues. No share buyback or dividend program is mentioned. Considering the market cap and mixed outlook, the stock price is likely to remain stable, with a neutral sentiment over the next two weeks.
Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript
Positive2-24
The company's earnings call highlights strong revenue growth, a successful stock repurchase program, and strategic pharmacy transitions to meet demand. Despite a decline in net income, the optimistic guidance and potential FDA approvals for relacorilant support a positive outlook. The Q&A section reveals confidence in resolving supply chain issues and potential new oncology standards. However, uncertainties with the FDA and price erosion concerns slightly temper the sentiment. Given the market cap, the stock is likely to react positively, with a predicted movement of 2% to 8% over the next two weeks.
Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents a mixed picture: revenue growth and strategic expansion in pharmacy capacity are positive, but the significant drop in net income and lack of priority review for the ovarian cancer NDA are concerns. The Q&A reveals confidence in handling increased volume and no downward pressure on margins, but management's vague responses on certain issues may worry investors. The market cap is moderate, suggesting a neutral stock price movement, balancing positive growth prospects with current financial challenges.
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Positive8-1
The earnings call summary and Q&A reveal strong revenue growth, a strategic sales force expansion, and a promising drug pipeline. Despite minor setbacks in pharmacy capacity impacting financial results, the company's stock repurchase program and optimistic future revenue expectations, particularly for relacorilant, are positive indicators. The Q&A also highlighted management's proactive measures to address pharmacy issues and expand market reach. With a market cap of $3.3 billion, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
CORT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
